Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of sonrotoclax alone and in combinations for relapsed or refractory multiple myeloma with t(11;14)
MOH_2023-12-05_013045Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonrotoclax in multiple myeloma (MM) (9 arms), sponsored by BeiGene. Primary endpoints: Safety and Tolerability. Started Nov 2023; status: completed.
02
Drugs
sonrotoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-12-05_013045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-05_013045.